

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF
ARTEMIS CARDIAC CARE PRIVATE LIMITED

Report on the Audit of the Ind AS Financial Statements

Opinion

We have audited the accompanying Ind AS financial statements of **ARTEMIS CARDIAC CARE PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at 31st March, 2024, the Statement of Profit and Loss (including the Statement of Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended 31st March 2024, and notes to the financial statements, including a summary of material accounting policies and other explanatory information together referred to as "Ind AS financial statements".

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2024, and its profit including other comprehensive income, changes in equity and its cash flows and for the year ended on that date.

Basis for Opinion

We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Ind AS financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Ind AS financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

Information other than the Ind AS financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report of the Board of Directors including annexures to the Board's Report, but does not include the Ind AS financial statements and our auditor's report thereon.

Our Opinion on the Ind AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



In connection with our audit of the Ind AS financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Ind AS financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Management and Those Charged with Governance for the Ind AS financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Ind AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibility for the Audit of the Ind AS financial Statements

Our objectives are to obtain reasonable assurance about whether the Ind AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Ind AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Ind AS financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Ind AS financial statements, including the disclosures, and whether the Ind AS financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatement in the Ind AS financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Ind AS financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work ; and (ii) to evaluate the effect of any identified misstatement in the Ind AS financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on other legal and regulatory requirements:-

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the "Annexure A", a statement on the matters specified in Paragraphs 3 and 4 of the Order.
2. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss (including other Comprehensive income), Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account.



- (d) In our opinion, the aforesaid Ind AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.
- (e) On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any impact of pending litigations on its financial position in its Ind AS financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv.
 - a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
 - v. The Company has not proposed, declared and paid any dividend during the year. Accordingly reporting under Rule 11(f) is not applicable to the Company.



- vi. Based on our examination, which included test checks, the Company has used accounting softwares for maintaining its books of account for the financial year ended March 31, 2024 which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the softwares. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2024.

3. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

According to information and explanation given to us, no managerial remuneration for the year ended March 31, 2024 has been paid/provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act.

For SCV & Co. LLP
CHARTERED ACCOUNTANTS
FIRM REGISTRATION No. 000235N/N500089



(SUNNY SINGH)
PARTNER

MEMBERSHIP No.516834
ICAI UDIN: 24516834BKBMNQ7016

PLACE: NOIDA

DATED: 08th MAY, 2024

Annexure "A" to the Independent Auditors' Report

Annexure referred to in paragraph 1 under the heading "Report on other legal and regulatory requirements" of our Report of even date.

In terms of the information and explanations sought by us and given by the company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- i. (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangibles assets.
- (b) Physical verification of the Property, Plant and Equipment has been conducted by the management during the year. All the Property, Plant and Equipment of the Company have not been physically verified by the management during the year but there is a regular phased programme of physical verification which, in our opinion, is reasonable having regard to the size of the Company and nature of its Property, Plant and Equipment. No material discrepancies were noticed on such verification.
- (c) There is no immovable property (other than properties where the Company is a lessee and lease agreements are duly executed in the favour of the lessee) held by the Company. Accordingly, the paragraphs 3(i)(c) of the Order is not applicable to the Company.
- (d) The Company has not revalued any of its Property, Plant and Equipment during the year.
- (e) Based on the information and explanations furnished to us, no proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. (a) Physical verification of inventory has been conducted by the management at reasonable intervals during the year and the coverage and procedure adopted by the management for verification is appropriate. No discrepancies were noticed during the physical verification of inventory as compared to book records by the management which could aggregate 10% or more for each class of inventory.
- (b) The Company has not been sanctioned working capital limits in excess of ₹ 5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.
- iii. During the year the Company has not made investments in, provided any guarantee or security or granted any loans or advances in nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties. Accordingly, the paragraph 3(iii) of the Order is not applicable to the Company.
- iv. In our opinion and according to the information and explanations given to us, there are no loans, investment, guarantees and securities granted in respect of which provisions of Sections 185 and 186 of the Companies Act, 2013 are applicable. Accordingly, the paragraph 3(iv) of the Order is not applicable to the Company.



- v. In our opinion and according to the information and explanations given to us, the company has not accepted any deposits or amounts which are deemed to be deposits within the meaning of section 73 of the Companies Act, 2013 and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- vi. In our opinion and according to the information and explanations given to us, the Companies (Cost Records and Audit) Rules, 2014 prescribed by Central Government under sub-section (1) of section 148 of the Companies Act, 2013 is not applicable to the Company. Accordingly, the paragraph 3(vi) of the Order is not applicable to the Company.
- vii. (a) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has been generally regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales tax, service tax, goods and services tax, duty of custom, duty of excise, value added tax, cess and other material statutory dues applicable to it to the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income tax, sales tax, service tax, goods and services tax, duty of custom, duty of excise, value added tax and cess and other material statutory dues were outstanding, as on 31st March 2024 for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us, and on the basis of our examination of the books of account, there are no dues of provident fund, employees' state insurance, income tax, sales tax, service tax, goods and services tax, duty of custom, duty of excise, value added tax and cess which have not been deposited on account of any dispute.
- viii. In our opinion and according to the information and explanations given to us, the Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 (43 of 1961) as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.
- ix. (a) According to the records of the Company examined by us and the information and explanations given to us, the Company has not defaulted in repayment of loans or other borrowings or in payment of interest to the lenders.
- (b) According to the records of the Company examined by us and the information and explanations given to us, the Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
- (c) Based on our audit procedures and according to information and explanations given by the management, the term loans obtained by the Company were applied for the purpose for which it was obtained.
- (d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the Ind AS financial statements of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company.
- (e) The Company does not have any subsidiaries, associates, joint ventures. Accordingly, the paragraph 3(ix)(e) of the Order is not applicable to the Company.



- (f) The Company does not have any subsidiaries, associates, joint ventures. Accordingly, the paragraph 3(ix)(f) of the Order is not applicable to the Company.
- x. (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, the paragraph 3(x)(a) of the Order is not applicable to the Company.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally convertible). Accordingly, the paragraph 3(x)(b) of the Order is not applicable to the Company.
- xi. (a) According to the information and explanations given to us, no fraud by the Company or no material fraud on the Company has been noticed or reported during the year.
- (b) During the year, no report under sub-section (12) of section 143 of the Companies Act, 2013 has been filed in Form ADT - 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government and up to the date of this report.
- (c) As represented to us by the management, no whistle blower Complaints received by the Company during the year.
- xii. The Company is not a Nidhi company as per the provisions of the Companies Act, 2013. Accordingly, provisions of paragraph 3(xii)(a) to 3(xii)(c) of the Order is not applicable to the Company.
- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act, 2013 where applicable and details of such transactions have been disclosed in the Ind AS financial statements as required by the applicable accounting standards.
- xiv. (a) The company does not have an internal audit system and is not required to have an internal audit system under the provisions of Section 138 of the Companies Act 2013. Therefore, the requirement to report under clause 3(xiv)(a) of the Order is not applicable to the Company.
- (b) The company does not have an internal audit system and is not required to have an internal audit system under the provisions of Section 138 of the Companies Act 2013. Therefore, the requirement to report under clause 3(xiv)(b) of the Order is not applicable to the Company.
- xv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him as referred to in section 192 of the Companies Act, 2013. Accordingly, provisions of paragraph 3(xv) of the Order is not applicable to the Company.
- xvi. (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934. Accordingly, provisions of paragraph 3(xvi)(a) to 3(xvi)(c) of the Order are not applicable to the Company.
- (b) Based on the information and explanations provided by the management of the Company, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016). We have not, however, separately evaluated whether the information provided by the management is accurate and complete. Accordingly, the requirement to report on clause 3 (xvi)(d) of the Order is not applicable to the Company.



- xvii. The Company has not incurred cash losses during the year. In the immediately preceding financial year the Company has incurred cash losses amounting to Rs. 40.18 Lakhs.
- xviii. There has been no resignation of the statutory auditors of the Company during the year and accordingly paragraph 3(xviii) of the Order is not applicable to the Company.
- xix. On the basis of the financial ratios disclosed in Note 27, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the Ind AS financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx. In our opinion and according to the information and explanations given to us, the provisions of Section 135 of the Companies Act 2013 is not applicable to the Company. Accordingly, provisions of paragraph 3(xx)(a) and 3(xx)(b) of the Order is not applicable to the Company.

For SCV & Co. LLP
CHARTERED ACCOUNTANTS
FIRM REGISTRATION No. 000235N/N500089



A handwritten signature in blue ink, appearing to be "Sunny Singh".

(SUNNY SINGH)
PARTNER
MEMBERSHIP No.516834
ICAI UDIN: 24516834BKBMNQ7016

PLACE: NOIDA
DATED: 08th MAY, 2024

Annexure “B” To the Independent Auditor’s Report

Annexure referred to in paragraph 2(f) under the heading “Report on other legal and regulatory requirements” of our report of even date.

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **ARTEMIS CARDIAC CARE PRIVATE LIMITED** (“the Company”) as of March 31, 2024 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by Institute of Chartered Accountants of India and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.



Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Ind AS financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For SCV & Co. LLP
CHARTERED ACCOUNTANTS
FIRM REGISTRATION No. 000235N/N500089



A handwritten signature in blue ink, appearing to read "Sunny Singh".

(SUNNY SINGH)
PARTNER

MEMBERSHIP No.516834
ICAI UDIN: 24516834BKBMNQ7016

PLACE: NOIDA
DATED: 08th MAY, 2024

Artemis Cardiac Care Private Limited
Balance Sheet as at 31st March, 2024

Particulars	Note No.	As at	As at
		31st March, 2024	31st March, 2023
		Rs. In Lacs	Rs. In Lacs
Assets			
Non-current assets			
Property, Plant and Equipment	2.1	1,980.76	2,154.36
Intangible assets	2.2	23.36	-
Intangible assets under development	2.3	-	3.58
Deferred Tax Assets (Net)	3	143.01	184.33
Non-Current Tax Assets (Net)	4	236.79	111.76
Other Financial Assets	10	0.56	-
Other Non-Current Assets	5	0.03	-
Total Non-Current Assets	A	2,384.51	2,454.03
Current Assets			
Inventories	6	98.84	124.23
Financial Assets			
i. Trade Receivables	7	1,132.38	846.80
ii. Cash and Cash Equivalents	8	135.30	120.26
iii. Other Bank Balances	8.1	205.00	141.00
iv. Loans & Advances	9	1.66	1.49
v. Other Financial Assets	10	23.35	8.40
Other Current Assets	5	13.67	9.78
Total Current Assets	B	1,610.20	1,251.96
Total Assets	C = A + B	3,994.71	3,705.99
Equity and Liabilities			
Equity			
Equity Share Capital	11	2,310.00	1,800.00
Other Equity	12	(501.30)	(502.21)
Total Equity	D	1,808.70	1,297.79
Liabilities			
Non-Current Liabilities			
Financial Liabilities			
i. Borrowings	13	1,123.00	1,533.14
Provisions	16	24.80	17.10
Total Non-Current Liabilities	E	1,147.80	1,550.24
Current Liabilities			
Financial Liabilities			
i. Borrowings	13	412.49	252.40
ii. Trade Payables	14	-	-
(A) Total Outstanding dues of Micro Enterprises and Small Enterprises		249.67	-
(B) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises		309.07	503.80
iii. Other Financial Liabilities	15	46.53	78.59
Provisions	16	4.74	3.34
Other Current Liabilities	17	15.71	19.83
Total Current Liabilities	F	1,038.21	857.96
Total Liabilities	G = E + F	2,186.01	2,408.20
Total Equity and Liabilities	H = D + G	3,994.71	3,705.99

Material Accounting Policies
See accompanying Notes to Financial Statements

2 to 38

As per our report of even date attached
For SCV & Co. LLP
Chartered Accountants
Firm Registration Number 000235N / N500089

(Sunny Singh)
Partner
Membership No. 516834
Place : Noida
Dated: 8th May 2024



For and on behalf of the Board of Directors
of Artemis Cardiac Care Private Limited

Dr. Devlina Chakravarty
[Director]
[DIN : 07107875]

Dr. Kapil Mohan
[Chief Executive Officer]

Place : Gurugram
Dated: 8th May 2024

Dr. (Brig.) Anil Khearpal
[Director]
[DIN : 09784377]

Joginder Singh
[Chief Financial Officer]

Poonam Makkar
[Company Secretary]



Artemis Cardiac Care Private Limited
Statement of Profit & Loss for the year ended 31st March, 2024

Particulars	Note No.	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
Income			
Revenue from Operations	18	3,334.58	2,321.41
Other Income	19	20.12	29.39
Total Income	(I)	3,354.70	2,350.80
Expenses			
Purchases of Pharmacy Drugs & Medical Consumables		859.98	691.61
Changes in Inventories	20	25.39	(59.35)
Employee Benefits Expense	21	545.85	411.55
Finance Costs	22	170.89	112.46
Depreciation and Amortization Expense	23	228.58	154.08
Other Expenses	24	1,481.39	1,266.36
Total Expenses	(II)	3,312.08	2,576.71
Profit Before Tax	III = (I - II)	42.62	(225.91)
Tax Expense			
Current Tax	25	-	-
Deferred Tax		41.42	(58.32)
Total Tax Expense	(IV)	41.42	(58.32)
Profit After Tax	V = (III - IV)	1.20	(167.59)
Other Comprehensive Income for the year			
Items that will not be reclassified to profit or loss			
Remeasurement of defined employee benefit plans (Refer note 29)		(0.39)	0.26
Income tax relating to items that will not be reclassified to profit or loss		0.10	(0.07)
Other Comprehensive Income	VI	(0.29)	0.19
Total Comprehensive Income	VII = (V+VI)	0.91	(167.40)
Earning Per Equity Share (Face Value Of Rs. 10/- Each)			
Basic(Rs.)	29	0.01	(1.22)
Diluted(Rs.)		0.01	(1.22)
Material Accounting Policies			
See accompanying Notes to Financial Statements	1 2 to 38		

For SCV & Co. LLP
Chartered Accountants
Firm Registration Number 000235N / NS000789

(Sunny Singh)
Partner
Membership No. 516834



Place : Noida
Dated: 8th May 2024

For and on behalf of the Board of Directors
of Artemis Cardiac Care Private Limited

Dr. Devlina Chakravarty
[Director]
[DIN : 07107875]

Dr. Kapil Mohan
[Chief Executive Officer]

Dr. (Brig.) Aril Khetarpal
[Director]
[DIN : 09784377]

Joginder Singh
[Chief Financial Officer]

Poonam Makkar
[Company Secretary]



Place : Gurugram
Dated: 8th May 2024

Artemis Cardiac Care Private Limited
Statement of cash flows for the year ended 31st March, 2024

Particulars	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
Cash flow from operating activities		
Profit before tax	42.62	(225.91)
Adjustments:		
Depreciation and amortisation	228.58	154.08
Interest Income	(17.47)	(4.35)
Finance Cost	170.89	112.46
Allowance for Expected Credit Loss	38.60	-
Loss/(profit) on sale/scrap of Property Plant and Equipment	-	10.04
Operating cash flow before working capital changes	463.22	46.31
Movements in working capital :		
Changes in trade receivables	(324.19)	(468.84)
Changes in inventories	25.39	(59.35)
Changes in loans(Current)	(0.17)	(1.02)
Changes in other Financial Assets	(0.56)	-
Changes in other financial assets (Current)	(14.94)	(5.74)
Changes in other current assets	(3.89)	(5.45)
Changes in trade payables	54.95	299.36
Changes in provisions(Non Current)	8.69	11.20
Changes in Other current liabilities(Current)	(4.12)	7.06
Changes in Other financial liabilities(Current)	(32.06)	(67.63)
Cash generated from operations	172.31	(244.10)
Income tax paid/(refund)	(125.02)	(42.38)
Net cash generated from operating activities (A)	47.29	(286.47)
Cash flow from investing activity		
Purchase of Property, Plant & Equipment(Including Capital Advances)	(74.80)	(1,047.59)
Proceeds from sale of Property, Plant & Equipment	-	0.34
Bank deposits having original maturity of more than 3 months	(64.00)	(141.00)
Interest received	17.47	4.35
Net cash (used in) investing activities (B)	(121.33)	(1,183.89)
Cash flow from financing activity		
Proceeds from borrowings	(0.00)	1,053.51
Repayment of borrowings	(250.03)	(348.88)
Proceeds from issue of Equity share capital	510.00	940.00
Interest paid	(170.89)	(112.46)
Net cash generated from financing activities (C)	89.08	1,532.17
Net increase in cash & cash equivalents (A+B+C)	15.04	61.81
Cash & cash equivalents at the beginning of the year	120.26	58.45
Cash & cash equivalents at the end of the year	135.30	120.26
Components of cash and cash equivalents		
Cash on hand	-	12.84
Balances with Banks: in current accounts	135.30	107.42
Total	135.30	120.26

As per our report of even date attached
For SCV & Co. LLP
Chartered Accountants
Firm Registration Number 00023817 / IN500089

(Sunny Singh)
Partner
Membership No. 516834

Place : Noida
Dated: 8th May 2024



For and on behalf of the Board of Directors
of Artemis Cardiac Care Private Limited

Dr. Devlina Chakravarty
[Director]
[DIN : 07107875]

Dr. (Brig.) Anil Khetarpal
[Director]
[DIN : 09784377]

Dr. Kapil Mohan
[Chief Executive Officer]
Place : Gurugram
Dated: 8th May 2024

Joginder Singh
[Chief Financial Officer]

Poonam Makkar
[Company Secretary]



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Statement of changes in Equity

1) Equity Share Capital

Particulars	Note	Amount
Balance as at 1st April 2023		1,800.00
Equity Share capital issued during the year		510.00
Balance as at 31st Mar, 2024	11	2,310.00

Balance as at 1st April 2022		860.00
Equity Share capital issued during the year		940.00
Balance as at March 31, 2023	11	1,800.00

2) Other Equity

Particulars	Note No.	Reserve & Surplus	Other Comprehensive Income	Total
		Retained Earnings	Remeasurements of the net defined benefit plans	
Balance as at 1st April 2022		(335.81)	1.00	(334.81)
Profit/ (Loss) for the year	12	(167.59)	-	(167.59)
Other Comprehensive Income (OCI) (net of tax)	12	-	0.19	0.19
Balance as at March 31, 2023	12	(503.40)	1.19	(502.21)
Balance as at 1st April 2023		(503.40)	1.19	(502.21)
Profit/ (Loss) for the year	12	1.20	-	1.20
Other Comprehensive Income (OCI) (net of tax)	12	-	(0.29)	(0.29)
Balance as at 31st Mar, 2024	12	(502.20)	0.90	(501.30)

Material Accounting Policies 1
See accompanying Notes to Financial Statements 2 to 38

As per our report of even date attached
For SCV & Co. LLP
Chartered Accountants
Firm Registration Number 000235N / N500089

(Sunny Singh)
Partner
Membership No. 516834

Place : Noida
Dated: 8th May 2024



For and on behalf of the Board of Directors
of Artemis Cardiac Care Private Limited

Dr. Devlina Chakravarty
[Director]
[DIN : 07107875]

Dr. Kapil Mohan
[Chief Executive Officer]

Place : Gurugram
Dated: 8th May 2024

Dr. (Brig.) Anil Khetarpal
[Director]
[DIN : 0978437]

Joginder Singh
[Chief Financial Officer]

Poonam Makkar
[Company Secretary]



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No. 2.1

Rs in Lacs

Property, Plant and Equipment

Particulars	Computers	Furniture & Fixtures	Office Equipments	Plant and Equipments	Vehicles	Total
Gross Block						
As at 1st April 2022	11.98	28.10	21.29	1,411.31	-	1,472.68
Additions during the year	14.97	38.09	2.17	1,014.01	-	1,069.24
Disposals / Discarded during the year	-	-	(11.83)	-	-	(11.83)
Adjustment during the year	-	-	-	-	-	-
As at 31st March, 2023	26.95	66.19	11.63	2,425.32	-	2,530.09
Additions during the year	2.75	0.20	0.43	48.49	-	51.87
Disposals / Discarded during the year	-	-	-	-	-	-
Adjustment during the year	-	-	-	-	-	-
As at 31st March, 2024	29.70	66.39	12.06	2,473.81	-	2,581.96
Accumulated Depreciation						
As at 1st April 2022	6.55	7.26	4.90	204.39	-	223.10
Charge for the year	5.50	5.52	2.85	140.21	-	154.08
Disposals / Discarded during the year	-	-	(1.45)	-	-	(1.45)
As at 31st March, 2023	12.05	12.78	6.30	344.60	-	375.73
Charge for the year	7.72	7.53	1.69	208.53	-	225.47
Disposals / Discarded during the year	-	-	-	-	-	-
As at 31st March, 2024	19.77	20.31	7.99	553.13	-	601.20
Net Block						
As at 31st March, 2023	14.90	53.41	5.33	2,080.72	-	2,154.36
As at 31st March, 2024	9.93	46.08	4.07	1,920.68	-	1,980.76

Note No. 2.2

Particulars	Intangible assets
Gross Block	
At Cost	
As at 1st April 2022	-
Additions during the year	-
Disposals / Discarded during the year	-
As at 31st March, 2023	-
Additions during the year	26.47
Adjustment during the year	-
As at 31st March, 2024	26.47
Amortization	
As at 1st April 2022	-
Charge for the year	-
Disposals / Discarded during the year	-
As at 31st March, 2023	-
Charge for the year	3.11
Disposals / Discarded during the year	-
As at 31st March, 2024	3.11
Net Block	
As at 31st March, 2023	-
As at 31st March, 2024	23.36

Note No. 2.3

Particulars	As at 31st March, 2024	As at 31st March, 2023
Intangible assets under development	-	3.58
Total	-	3.58

Intangible assets under development ageing schedule for the year ended March 31, 2024 and March 31, 2023 is as follows:

Particulars	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Intangible assets under development	3.58	-	-	-	3.58
Total Intangible assets under development	3.58	-	-	-	3.58



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Deferred tax assets / (liabilities) in relation to :	As at 1st April, 2023	Credit / (Charge) to Profit or loss	Credit / (Charge) to Other Comprehensive Income	As at 31st March, 2024
3	Deferred Tax Assets / (Liabilities) (Net) The following is the analysis of deferred tax assets / liabilities recognised in statement of profit and loss and Other Comprehensive Income				
	Property, plant and equipment	(71.06)	(11.61)	-	(82.67)
	Employee Benefits	5.69	1.64	0.10	7.43
	Unabsorbed business losses as per Income Tax Act	240.38	(54.53)	-	185.85
	Others	9.32	23.08	-	32.40
		<u>184.33</u>	<u>(41.42)</u>	<u>0.10</u>	<u>143.01</u>

Note: Deferred tax assets and deferred tax liabilities have been offset as they are governed by the same taxation laws.

Note No.	Deferred tax assets / (liabilities) in relation to :	As at 1st April, 2022	Credit / (Charge) to Profit or loss	Credit / (Charge) to Other Comprehensive Income	As at 31st March, 2023
3	Deferred Tax Assets / (Liabilities) (Net) The following is the analysis of deferred tax assets / liabilities recognised in statement of profit and loss and Other Comprehensive Income				
	Property, plant and equipment	(46.08)	(24.98)	-	(71.06)
	Employee Benefits	2.64	3.12	(0.07)	5.69
	Unabsorbed business losses as per Income Tax Act	168.01	72.36	-	240.38
	Others	1.51	7.82	-	9.32
		<u>126.08</u>	<u>58.32</u>	<u>(0.07)</u>	<u>184.33</u>

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
4	Income tax assets		
	Non Current	236.79	111.76
	Income Tax Recoverable	<u>236.79</u>	<u>111.76</u>
	Total		

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
5	Other Assets (Unsecured, Considered good)		
	Non-Current		
	Prepaid Expenses	0.03	-
	Total	<u>0.03</u>	<u>-</u>
	Current		
	(Unsecured, Considered good)		
	Advances recoverable	1.54	1.43
	Balance with statutory authorities	-	3.70
	Prepaid Expenses	12.13	4.65
		<u>13.67</u>	<u>9.78</u>

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
6	Inventories (Valued at lower of cost or net realisable value)		
	Stock of Pharmacy Drugs & Medical Cosumables	98.84	124.23
	Total	<u>98.84</u>	<u>124.23</u>



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2023

Note No.	Particulars	As at	
		31st March, 2024	31st March, 2023
		Rs. In Lacs	Rs. In Lacs
7	Trade Receivables (Unsecured)		
	Current		
	Considered good	1,207.84	883.67
	Less: Expected Credit Loss Allowance	75.46	36.87
		1,132.38	846.80

In accordance with Ind AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss towards expected risk of delays and default in collection.

The Company uses judgements in making certain assumptions and selecting inputs to determine impairment of these trade receivables, based on the Company's historical experience towards potential billing adjustments, delays and defaults at the end of each reporting period. The provision matrix used to compute the expected credit loss allowance for different categories of trade receivables is as follows.

Ageing	ECL %
Not Due	0.1%
Less than 6 Months	2%
6 Months - 1 Year	5%
1-2 Years	20%
2-3 Years	50%
More than 3 Years	100%

The movement in allowance for expected credit loss in respect of trade receivables during the year was as follows:

Allowance for expected credit loss	As At	As At
	31st March, 2024	31st March, 2023
Opening balance	36.87	5.22
Expected Credit loss created during the year	38.59	31.65
Expected Credit loss reversed during the year	-	-
Closing balance	75.46	36.87

Trade Receivables ageing schedule for the year ended as on March 31, 2024 and March 31, 2023:

Particulars	Not Due	Less than 6 Months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Unbilled Receivables	Total
Undisputed Trade receivables – considered good	207.68	462.39	355.14	167.52	8.49	6.62	-	1,207.84
	<i>203.83</i>	<i>414.14</i>	<i>175.69</i>	<i>66.36</i>	<i>12.62</i>	-	<i>11.03</i>	<i>883.67</i>
Undisputed Trade receivables – credit impaired	-	-	-	-	-	-	-	-
Disputed Trade receivables – considered good	-	-	-	-	-	-	-	-
Disputed Trade receivables – credit impaired	-	-	-	-	-	-	-	-
Less: Allowance for Credit Loss	0.22	9.75	18.71	35.32	4.84	6.62	-	75.46
	<i>0.21</i>	<i>8.29</i>	<i>8.78</i>	<i>13.27</i>	<i>6.32</i>	-	-	<i>36.87</i>
Total Trade Receivables	207.46	452.64	336.43	132.20	3.65	-	-	1,132.38
	<i>203.62</i>	<i>405.85</i>	<i>166.91</i>	<i>53.09</i>	<i>6.30</i>	-	<i>11.03</i>	<i>846.80</i>

* Previous Year Figures in Italics



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
8	Cash & Cash Equivalent		
	Balance with Banks:		
	- In Current Accounts	135.30	107.42
	Cash on hand	-	12.84
		135.30	120.26
8.1	Other Bank Balances		
	Balance with Banks:		
	- Fixed Deposit with Banks having remaining maturity more than 3 months but less than 12 months	205.00	141.00
		205.00	141.00
9	Loans		
	Current		
	Loans & advances to Employees	1.66	1.49
		1.66	1.49
10	Other Financial Assets		
	Non Current		
	Loans & advances to Employees	0.56	
		0.56	-
	Current		
	Unbilled Revenue(Accrued operating income)	12.55	6.38
	Accrued interest on Fixed Deposit	10.80	2.02
		23.35	8.40



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	As at	As at
		31st March, 2024 Rs. In Lacs	31st March, 2023 Rs. In Lacs
11	Equity Share Capital:		
	Authorised Shares (in nos.) 2,50,00,000 (Previous Year 2,50,00,000) Equity Shares of Rs. 10/- each	2,500.00	2,500.00
	Issued, Subscribed & Paid Up Shares (in nos.)		
	231,00,000 (Previous Year:1,80,00,000) Equity Shares of Rs. 10/- each	2,310.00	1,800.00
	Total issued, subscribed and fully paid up capital	2,310.00	1,800.00

a. Reconciliation of the equity shares at the beginning and at the end of the year

Reconciliation	As at As on 31st March, 2024		As at 31st March, 2023	
	Nos.	Rs. In Lacs	Nos.	Rs. In Lacs
Shares outstanding at the beginning of the year	1,80,00,000	1,800.00	86,00,000	860.00
Shares issued during the year	51,00,000	510.00	94,00,000	940.00
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	2,31,00,000	2,310.00	1,80,00,000	1,800.00

b. Terms/rights attached to Equity Shares

The company has only one class of equity shares having a par value of Rs. 10 per share. Each holder of equity shares is entitled to one vote per share, where voting is held by show of hands. In case of Poll each holder of equity share is entitled to Number of votes against Number of shares held.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the equity share holders.

c. Equity Shares held by holding company :

Name of the Shareholder	As on 31st March, 2024		As at 31st March 2023	
	No. of Shares	Rs. In Lacs	No. of Shares	Rs. in Lacs
Artemis Medicare Services Limited - holding company	1,50,15,000	1,502	1,17,00,000	1,170

d. Details of Shareholders holding more than 5% Equity Shares in the Company:

Name of the Shareholder	As on 31st March, 2024		As at 31st March 2023	
	No. of Shares	% of Holding	No. of Shares	% of Holding
Artemis Medicare Services Limited - holding company	1,50,15,000	65%	1,17,00,000	65%
Philips Medical Systems Nederland BV	80,85,000	35%	63,00,000	35%

e. Details of Equity Shares Held by the Promoters at the end of the year

Promoter Name	As on 31st March, 2024		As at 31st March 2023		% Change in Holding
	No. of Shares	% of Total Shares	No. of Shares	% of Total Shares	
Artemis Medicare Services Limited - holding company	1,50,15,000	65%	1,17,00,000	65%	-
Philips Medical Systems Nederland BV	80,85,000	35%	63,00,000	35%	-
Total	2,31,00,000	100%	1,80,00,000	100%	



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
12	Other Equity:		
	Retained earnings		
	Balance as per last financial statements	(502.21)	(334.81)
	Profit / (Loss) for the year	1.20	(167.59)
	Other comprehensive income arising from re-measurement of defined benefit obligation net of income tax	(0.29)	0.19
	Balance at end of the year	(501.30)	(502.21)
	Total Other Equity	(501.30)	(502.21)

Retained Earnings

Retained earnings represents the profits that the Company has earned till date, less any transfer to general reserve and dividends or other distributions to shareholders etc.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
13	Borrowings		
	Non Current		
	Term Loans		
	<u>From Banks</u>		
	- Indian Rupee loans from Banks (secured at amortised cost)	1,123.00	1,533.14
	Total	1,123.00	1,533.14
	Current		
	Term Loans		
	Current maturities of long term borrowings	412.49	232.40
	Loans Repayable on Demand		
	<u>From Others</u>		
	- Indian Rupee loan* (Unsecured)	-	20.00
		412.49	252.40

* Includes loan taken from Holding Company which is repayable on demand

1. Indian Rupee Loans from Banks include :

a) Term loans of Rs. 1535.49 Lacs (As at 31st March, 2023 Rs. 1765.54 Lacs) from Scheduled Bank carries interest as linked with one year MCLR .The loans are secured by the charge on entire movable fixed assets and second charge on current assets. Further, these loans are secured by corporate guarantee given by holding company.

Repayment Schedule	Rs. In Lacs
FY 2024-25	412.49
FY 2025-26	536.33
FY 2026-27	495.42
FY 2027-28	93.62
Total	1,537.86



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
14	Trade payables		
	Total Outstanding dues of Micro Enterprises and Small Enterprises (Refer Note 30)	249.67	-
	Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	309.07	503.80
	Total	558.74	503.80

Trade payables ageing schedule for the year ended as on March 31, 2024 and March 31, 2023:

Particulars	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
1. MSME	249.67	-	-	-	249.67
	-	-	-	-	-
2. Others	309.07	-	-	-	309.07
	503.80	-	-	-	503.80
3. Disputed Dues-MSME	-	-	-	-	-
3. Disputed Dues-Others	-	-	-	-	-
	-	-	-	-	-
Total Trade Payable	558.74	-	-	-	558.74
	<i>503.80</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>503.80</i>

* Previous Year Figures in Italics

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
15	Other Financial Liabilities		
	Interest Accrued but not due on borrowings	5.91	6.70
	Other Payable*	38.93	68.06
	Advance from Customers	-	-
	Security Deposits	1.69	3.83
	Total	46.53	78.59

* Other payable includes payments due on account of capital items, due to employees.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
16	Provisions		
	<u>Non- Current</u>		
	Provision for Employee Benefits		
	Leave Benefits	17.97	13.42
	Gratuity	6.83	3.68
	(Refer Note 31)		
	Total	24.80	17.10
	<u>Current</u>		
	Provision for Employee Benefits		
	Leave Benefits	4.54	3.33
	Gratuity	0.20	0.01
	(Refer Note 31)		
	Total	4.74	3.34

Note No.	Particulars	As at 31st March, 2024 Rs. In Lacs	As at 31st March, 2023 Rs. In Lacs
17	Other Liabilities		
	Current		
	Taxes and other statutory dues*	15.71	19.83
	Total	15.71	19.83

*Taxes and other statutory dues includes Withholding Tax, Goods and Services Tax contribution of PF, ESI etc.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	31st March, 2024 For the year ended Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
18	Revenue from Operations		
	Sale of Services		
	Revenue from Health Care Services	3,270.39	2,142.46
	Sale of Goods		
	Sale of Pharmacy Drugs & Medical Consumables	64.19	178.95
	Total	3,334.58	2,321.41

Note No.	Particulars	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
19	Other Income		
	Interest Income		
	- From Bank deposits	11.44	7.41
	- From Income tax refund	6.03	4.35
	Other Non-Operating Income	2.65	3.40
	Liabilities no longer required written back	-	14.23
	Total	20.12	29.39

Note No.	Particulars	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
20	(Increase) / Decrease in Inventories of Pharmacy Drugs & Medical Consumables		
	Inventories at the beginning of the year	124.23	64.88
	Inventories at the end of the year	98.84	124.23
	Total	25.39	(59.35)



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
21	Employee Benefits Expense		
	Salaries, Wages and Bonus	486.16	371.05
	Contribution to Provident and Other Funds	38.92	26.72
	Gratuity Expenses(Refer Note 31)	3.23	2.20
	Employee Welfare Expenses	17.54	11.58
	Total	545.85	411.55

Note No.	Particulars	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
22	Finance Costs		
	Interest expense on financial liabilities measured at amortised cost		
	- On term Loans	154.57	108.03
	Other Borrowing Costs	11.73	2.52
	Bank Charges	4.59	1.91
	Total	170.89	112.46

Note No.	Particulars	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
23	Depreciation and amortization expense		
	Depreciation of property, plant and equipment	225.47	154.08
	Amortization of Intangible assets	3.11	-
	Total	228.58	154.08



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note No.	Particulars	For the year ended 31st March, 2024 Rs. in Lacs	For the year ended 31st March, 2023 Rs. in Lacs
24	Other expenses	7.82	1.83
	Rent - Lease Rent	58.53	27.72
	Legal & Professional Fees	-	0.58
	Equipment Hire Charges	38.60	31.65
	Provision for Expected credit loss	82.92	47.38
	Patient Facility Maintenance	5.03	2.04
	Patient Food & Beverages Expenses	21.80	20.71
	Travelling & Conveyance	51.47	82.84
	Advertisement & Business Promotion	214.36	108.10
	Medical Consultancy including facilitation charges		
	<u>Auditors Remuneration</u>	2.57	1.50
	- Statutory Audit Fee	0.89	0.59
	-Tax Audit Fee	1.42	0.89
	- Others Services & Certification	7.23	10.75
	Printing & Stationery	1.63	1.62
	Communication Expenses	5.89	5.47
	Outsource Lab Test Charges	10.84	4.46
	Security Charges	737.16	678.19
	Fee paid to doctors	76.42	63.44
	Power & Fuel		
	Repairs and Maintenance	126.92	111.60
	- Machinery	25.05	22.18
	- Others	2.53	1.78
	Insurance	1.85	30.96
	Rates & Taxes		
	Loss on Sale / Scrap of Property, Plant and Equipment (Net)	-	10.04
	Miscellaneous Expenses	0.46	0.05
	Total	1,481.39	1,266.36



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

INCOME TAX

Note No.	Particulars	For the year ended	For the year ended
		31st March, 2024	31st March, 2023
		Rs. in Lacs	Rs. in Lacs
25	Amount recognised in Statement of Profit & Loss		
	Current Tax		
	(a) In respect of the current year		
	(b) Earlier years tax provision written back		
	Deferred Tax		
	(a) In respect of the current year	41.42	(58.32)
	Tax expense recognised through statement of profit and loss	41.42	(58.32)
	Recognised in Other Comprehensive Income (OCI)		
	Deferred tax		
	In respect of the current year	0.10	(0.07)
	Tax credit recognised through Other Comprehensive Income	0.10	(0.07)
	The income tax expense for the year can be reconciled to the accounting profit as follows:		
	Profit before tax	42.62	(225.91)
	Enacted income tax rate in India	25.17%	27.82%
	Income tax calculated	10.73	(62.85)
	Change in enacted tax rate	15.07	-
	Others	15.62	4.53
	Income tax expense recognised in statement of profit & loss	41.42	(58.32)



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

1.1 Nature of operations

Artemis Cardiac Care Private Limited ("The Company") was incorporated on 14th Jan, 2019 with an object of developing, operating and managing multiple cardiac centres with interventional & diagnostics cardiology and critical care capability in private & public hospitals.

1.2 Statement of Material Accounting Policies

a) Statement of compliance

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 (the "Act") read together with Companies Ind AS rules 2015.

The financial statements were approved by the Company's Board of Directors on 8th May 2024

b) Basis of preparation and presentation

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Historical Cost is generally based on the fair value of the consideration given in exchange of goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company taken into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and / or disclosure purposes in these financial statements is determined on such a basis.

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2, or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the assets or liabilities either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

c) Property, Plant and Equipment (PPE)

Property, Plant and Equipment are stated at cost (or revalued amounts, as the case may be), less accumulated depreciation and impairment loss, if any. Cost comprises the purchase price and any attributable cost of bringing the property, plant and equipment to its working condition for its intended use. Borrowing costs relating to acquisition of property, plant and equipment which takes substantial period of time to get ready for its intended use are also included to the extent they relate to the period till such property, plant and equipment are ready to be put to use.

The cost of an item of property, plant and equipment is the cash price equivalent at the recognition date. If payment is deferred beyond normal credit terms, the difference between the cash price equivalent and the total payment is recognised as interest over the period of credit, unless such interest is capitalised as per borrowing cost.

The Company identifies and determines separate useful life of each major component of the property, plant and equipment, if they have useful life that is materially different from that of the remaining asset, as per Schedule II of Companies Act, 2013.

d) Depreciation on Property, Plant and Equipment

Depreciation on all of the property, plant and equipment on the cost of assets less their residual values on straight line method over the useful lives as indicated in Part C of Schedule II of the Companies Act, 2013. Depreciation Methods, useful lives and residual values are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

Depreciation commences when the fixed assets are ready for their intended use. Depreciation is provided on a straight line based on the estimated useful life of PPE as per management internal assessment, which is as follows:

Assets	Useful Life as per Schedule II
Plant & Machinery	7-15 Years
Office Equipments	5 Years
Computers	3 Years
Furnitures & Fittings	10 Years
Vehicles	8 Years

e) Intangible Assets

Intangible assets acquired separately are measured on initial recognition at cost less accumulated amortisation and accumulated impairment losses, if any.

Cost is the amount of cash or cash equivalents paid or the fair value of other consideration given to acquire an asset at the time of its acquisition or construction, or, when applicable, the amount attributed to that asset when initially recognised in accordance with the specific requirements of other Indian Accounting Standards.

f) Leases

Where the Company is the lessee

The Company's lease asset classes primarily consist of leases for buildings. The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: (i) the contract involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset.

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

Certain lease arrangements includes the options to extend or terminate the lease before the end of the lease term. ROU assets and lease liabilities includes these options when it is reasonably certain that they will be exercised.

The right-of-use assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. Right of use assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates. Lease liabilities are remeasured with a corresponding adjustment to the related right of use asset if the Company changes its assessment if whether it will exercise an extension or a termination option. Lease liability and ROU asset have been separately presented in the Balance Sheet and lease payments have been classified as financing cost.

Where the Company is the lessor

Leases for which the Company is a lessor is classified as a finance or operating lease. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Assets subject to operating leases are included in PPE. Rental income on operating lease is recognized in the statement of profit and loss on a straight-line basis over the lease term. Where the rentals are structured solely to increase in line with expected general inflation to compensate for the Company's expected inflationary cost increases, such increases are recognized in the year in which such benefits accrue.

Costs, including depreciation, are recognized as an expense in the statement of profit and loss. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased assets and recognised on a straight line basis over the lease term.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

g) Inventories

Inventories consisting of pharmacy drugs and medical consumables are measured at the lower of cost and net realisable value. The cost of all categories of inventories is based on the Weighted Average Cost method.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

h) Revenue recognition

Revenue is measured at the transaction price. Revenue is reduced for returns, trade allowances for deduction, rebates, taxes and amounts collected on behalf of third parties.

The Company applies the revenue recognition criteria to each separately identifiable component of the Revenue transaction as set out below:

Sale of Pharmacy Drugs and Medical supplies

Revenue from the sale of pharmacy drugs and medical supplies is recognised, at a point of time when the control of the goods has passed to the buyer i.e. at the point of sale/ delivery to the customer at an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods. Sale is net of sales returns, discounts & Goods & Services Tax.

Income from Operations

Revenue is recorded when the performance obligation is satisfied. For Out Patient Customer, services are simultaneously received and consumed by the patient. For In patient customers, revenue is recognized as services are performed over the period. Revenue for the ongoing services at the reporting date is recognized as unbilled revenue. The income is stated net of discounts and price differences as per the terms of contract.

Interest

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the applicable interest rate.

i) Employees Benefits

Short term employee benefits

Employee benefits payable wholly within twelve months of receiving services are classified as short-term employee benefits. These benefits include salary and wages, bonus and exgratia. The undiscounted amount of short-term employee benefits to be paid in exchange for employee services is recognized as an expense as the related service is rendered by the employees.

Post employment benefits

Defined contribution plans

A defined contribution plan is post-employment benefit plan under which an entity pays specified contributions to separate entity and has no obligation to pay any further amounts. The Company makes specified obligations towards employee provident fund and employee state insurance to Government administered provident fund scheme and ESI scheme which is a defined contribution plan. The Company's contributions are recognized as an expense in the statement of profit and loss during the period in which the employee renders the related service.

Defined benefit plans

The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned and returned for services in the current and prior periods; that benefit is discounted to determine its present value. The calculation of Company's obligation under the plan is performed periodically by a qualified actuary using the projected unit credit method.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognised immediately in the statement of profit and loss.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

Compensated absences

The employees can carry-forward a portion of the unutilized accrued compensated absences and utilize it in future service periods. The Company records an obligation for such compensated absences in the period in which the employee renders the services that increase this entitlement. The obligation is measured on the basis of independent actuarial valuation using the projected unit credit method.

j) Income taxes

Income tax expense represents the sum of the tax currently payable and deferred tax.

i) Current Tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The current tax is calculated using tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Current income-tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India and tax laws prevailing in the respective tax jurisdictions where the Company operates.

ii) Deferred tax

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in computation of taxable profit.

Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized.

Deferred tax is measured based on tax rates and tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities. Deferred tax assets are recognized only to the extent, that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that is no longer probable that sufficient taxable profits will be available to allow all part of assets to be recovered.

Deferred tax is measured based on tax rates and tax laws enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities.

iii) Current and deferred tax for the year

Current and deferred tax are recognized in the statement of profit and loss, except when they relate to items that are recognized in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognized in other comprehensive income or directly in equity respectively.

k) Earnings Per share

Basic earnings per share is being calculated by dividing net profit or loss for the year (including prior period items, if any) attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

l) Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

m) Financial Instrument

Financial assets and financial liabilities are recognised when a Company becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss.

All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace.

All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets

Classification of financial assets

Financial Assets that meet the following conditions are subsequently measured at amortised cost (except for financial assets that are designated As at fair value through profit or loss on initial recognition):

- i) the assets is held within a business model whose objective is to hold assets in order to collect contractual cash flows ; and
- ii) the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial Assets that meet the following conditions are subsequently measured at fair value through other comprehensive income (except for financial assets that are designated As at fair value through profit or loss on initial recognition):

- i) the assets is held within a business model whose objective is achieved both by collecting contractual cash flows and selling financial assets; and
- ii) the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Interest income is recognised in profit or loss for FVTOCI financial assets. For the purposes of recognising foreign exchange gains and losses, FVTOCI financial assets are treated as financial assets measured at amortised cost. Thus, the exchange differences on the amortised cost are recognised in profit or loss and other changes in the fair value of FVTOCI financial assets are recognised in other comprehensive income and accumulated under the heading of 'Reserve for financial assets through other comprehensive income'. When the investment is disposed of, the cumulative gain or loss previously accumulated in this reserve is reclassified to profit or loss.

All other financial assets are subsequently measured at fair value.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Income is recognised on an effective interest basis for debt instruments other than those financial assets classified As at FVTPL. Interest income is recognised in profit or loss and is included in the "Other income" line item.



Note
No.

Financial assets at fair value through profit or loss (FVTPL)

A financial asset that meets the amortised cost criteria or debt instruments that meet the FVTOCI criteria may be designated As at FVTPL upon initial recognition if such designation eliminates or significantly reduces a measurement or recognition inconsistency that would arise from measuring assets or liabilities or recognising the gains and losses on them on different bases. The Company has not designated any debt instrument As at FVTPL.

Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any gains or losses arising on remeasurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any dividend or interest earned on the financial asset and is included in the 'Other income' line item. Dividend on financial assets at FVTPL is recognised when the Company's right to receive the dividends is established, it is probable that the economic benefits associated with the dividend will flow to the entity, the dividend does not represent a recovery of part of cost of the investment and the amount of dividend can be measured reliably.

Impairment of financial assets

The Company applies the expected credit loss model for recognising impairment loss on financial assets measured at amortised cost, debt instruments at FVTOCI, lease receivables, trade receivables, and other contractual rights to receive cash or other financial asset, and financial guarantees not designated As at FVTPL.

Expected credit losses are the weighted average of credit losses with the respective risks of default occurring as the weights. Credit loss is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the Company expects to receive (i.e. all cash shortfalls), discounted at the original effective interest rate (or credit-adjusted effective interest rate for purchased or originated credit impaired financial assets). The Company estimates cash flows by considering all contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) through the expected life of that financial instrument.

The Company measures the loss allowance for a financial instrument at an amount equal to the lifetime expected credit losses if the credit risk on that financial instrument has increased significantly since initial recognition. If the credit risk on a financial instrument has not increased significantly since initial recognition, the Company measures the loss allowance for that financial instrument at an amount equal to 12-month expected credit losses. 12-month expected credit losses are portion of the life-time expected credit losses and represent the lifetime cash shortfalls that will result if default occurs within the 12 months after the reporting date and thus, are not cash shortfalls that are predicted over the next 12 months.

If the Company measured loss allowance for a financial instrument at lifetime expected credit loss model in the previous period, but determines at the end of a reporting period that the credit risk has not increased significantly since initial recognition due to improvement in credit quality as compared to the previous period, the Company again measures the loss allowance based on 12-month expected credit losses.

When making the assessment of whether there has been a significant increase in credit risk since initial recognition, the Company uses the change in the risk of a default occurring over the expected life of the financial instrument instead of the change in the amount of expected credit losses. To make that assessment, the Company compares the risk of a default occurring on the financial instrument As at the reporting date with the risk of a default occurring on the financial instrument As at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition.

For trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 115, the Company always measures the loss allowance at an amount equal to lifetime expected credit losses.

Further, for the purpose of measuring lifetime expected credit loss allowance for trade receivables, the Company has used a practical expedient as permitted under Ind AS 109. This expected credit loss allowance is computed based on a provision matrix which takes into account historical credit loss experience and adjusted for forward looking information.

The impairment requirements for the recognition and measurement of a loss allowance are equally applied to debt instruments at FVTOCI except that the loss allowance is recognised in other comprehensive income and is not reduced from the carrying amount in the balance sheet.



Note
No.

Derecognition of financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

On derecognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognised in other comprehensive income and accumulated in equity is recognised in profit or loss if such gain or loss would have otherwise been recognised in profit or loss on disposal of that financial asset.

On derecognition of a financial asset other than in its entirety (e.g. when the Company retains an option to repurchase part of a transferred asset), the Company allocates the previous carrying amount of the financial asset between the part it continues to recognise under continuing involvement, and the part it no longer recognises on the basis of the relative fair values of those parts on the date of the transfer. The difference between the carrying amount allocated to the part that is no longer recognised and the sum of the consideration received for the part no longer recognised and any cumulative gain or loss allocated to it that had been recognised in other comprehensive income is recognised in profit or loss if such gain or loss would have otherwise been recognised in profit or loss on disposal of that financial asset. A cumulative gain or loss that had been recognised in other comprehensive income is allocated between the part that continues to be recognised and the part that is no longer recognised on the basis of the relative fair values of those parts.

Foreign exchange gains and losses

The fair value of financial assets denominated in a foreign currency is determined in that foreign currency and translated at the spot rate at the end of each reporting period. For foreign currency denominated financial assets measured at amortised cost and FVTPL, the exchange differences are recognised in statement of profit and loss since there are no designated hedging instruments in a hedging relationship.

Financial liabilities

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

However, financial liabilities that arise when a transfer of a financial asset does not qualify for derecognition or then the continuing involvement approach applies, financial guarantee contracts issued by the Company, and commitments issued by the Company to provide a loan at below-market interest rate are measured in accordance with the specific accounting policies set out below.

Financial liabilities are classified As at FVTPL when the financial liability is either contingent consideration recognised by the Company as an acquirer in a business combination to which Ind AS 103 applies or is held for trading or it is designated As at FVTPL.

A financial liability is classified as held for trading if:

- i) it has been incurred principally for the purpose of repurchasing it in the near term; or
- ii) on initial recognition it is part of a portfolio of identified financial instruments that the company manages together and has a recent actual pattern of short-term profit-taking; or
- iii) it is a derivative that is not designated and effective as a hedging instrument.

Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on remeasurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the 'Other income' line item.

However, for non-held-for-trading financial liabilities that are designated As at FVTPL, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognised in other comprehensive income, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss, in which case these effects of changes in credit risk are recognised in profit or loss. The remaining amount of change in the fair value of liability is always recognised in profit or loss. Changes in fair value attributable to a financial liability's credit risk that are recognised in other comprehensive income are reflected immediately in retained earnings and are not subsequently reclassified to profit or loss.

Gains or losses on financial guarantee contracts and loan commitments issued by the Company that are designated by the Company As at fair value through profit or loss are recognised in profit or loss.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

Financial liabilities subsequently measured at amortised cost

Financial liabilities that are not held-for-trading and are not designated As at FVTPL are measured at amortised cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item.

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the net carrying amount on initial recognition.

Financial guarantee contracts

A financial guarantee contract is a contract that requires the issuer to make specified payments to reimburse the holder for a loss it incurs because a specified debtor fails to make payments when due in accordance with the terms of a debt instrument.

Financial guarantee contracts issued by a group entity are initially measured at their fair values and, if not designated As at FVTPL, are subsequently measured at the higher of:

- i) the amount of loss allowance determined in accordance with impairment requirements of Ind AS 109; and
- ii) the amount initially recognised less, when appropriate, the cumulative amount of income recognised in accordance with the principles of Ind AS115.

Foreign exchange gains and losses

For financial liabilities that are denominated in a foreign currency and are measured at amortised cost at the end of each reporting period, the foreign exchange gains and losses are determined based on the amortised cost of the instruments and are recognised in 'Other income'.

The fair value of financial liabilities denominated in a foreign currency is determined in that foreign currency and translated at the spot rate at the end of the reporting period. For financial liabilities that are measured As at FVTPL, the foreign exchange component forms part of the fair value gains or losses and is recognised in profit or loss.

Derecognition of financial liabilities

The Company derecognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or have expired. An exchange between with a lender of debt instruments with substantially different terms is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, a substantial modification of the terms of an existing financial liability (whether or not attributable to the financial difficulty of the debtor) is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in statement of profit & loss.

n) Provisions & Contingencies

Provisions are recognised when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material). When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

o) Contingent Liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by occurrence or non-occurrence of one or more of uncertain future events beyond the control of company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the an obligation. A contingent liability also arises in the extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably its existence in the financial statements. Company does not recognize the contingent liability but disclosed its existence in financial statements.

p) Cash and Cash Equivalents

Cash and cash equivalents for the purposes of cash flow statement are comprise of cash at bank and cash in hand and short-term investments with an original maturity of three months or less.

26 Segmental Reporting

Operating segments

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Healthcare services'. Accordingly, there are no additional disclosure to be provided under Ind AS 108, other than those already provided in the financial statements.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the year ended 31st March 2024

Note 27: Analytical Ratios

Note 27.1: Ratio

Particulars	Units	31st March 2024	31st March 2023	% change from March 31, 2023 to Mar 31, 2024
Current Ratio	Times	1.55	1.46	6.28
Debt-Equity Ratio	Times	0.85	1.38	(38.30)
Debt Service Coverage ratio	Times	0.95	0.21	343.77
Inventory Turnover ratio	Times	7.94	6.69	18.71
Trade Receivable Turnover Ratio	Times	3.37	3.79	(11.11)
Trade Payable Turnover Ratio	Times	1.62	1.95	(17.12)
Net Capital Turnover Ratio	Times	5.83	5.89	(1.05)
Net Profit ratio	Percentage	0.00	(0.07)	(100.50)
Return on Equity ratio	Percentage	0.00	(0.18)	(100.42)
Return on Capital Employed	Percentage	0.06	(0.04)	(273.52)
Return on Investment	Percentage	-	-	-

Note 27.2: Elements of Ratio

(₹ in Lacs)

Ratios	31st March 2024		31st March 2023	
	Numerator	Denominator	Numerator	Denominator
Current ratio	1,610.20	1,038.21	1,251.96	857.96
Debt- Equity Ratio	1,535.50	1,808.70	1,785.54	1,297.79
Debt Service Coverage ratio	400.67	420.92	98.96	461.35
Inventory Turnover ratio	885.37	111.53	632.26	94.55
Trade Receivable Turnover Ratio	3,334.58	989.59	2,321.41	612.38
Trade Payable Turnover Ratio	859.98	531.27	691.61	354.12
Net Capital Turnover Ratio	3,334.58	571.99	2,321.41	394.00
Net Profit Ratio	1.20	3,334.58	(167.59)	2,321.41
Return on Equity ratio	1.20	1,553.25	(167.59)	911.49
Return on Capital Employed	213.51	3,344.20	(113.45)	3,083.33
Return on Investment	NA	NA	NA	NA

Note 27.3: Consideration of Element of Ratio

- i. Current Ratio: Numerator= Current Assets
Denominator= Current Liabilities
- ii. Debt-Equity Ratio: Numerator= Total Debt
Denominator= Total Equity - Revaluation Reserve
- iii. Debt Service Coverage ratio: Numerator= Profit after Tax + Finance cost + Depreciation
Denominator= Repayment of Borrowings + Interest on
- iv. Inventory Turnover ratio: Numerator= Cost of Goods Sold
Denominator= Average Inventory
- v. Trade Receivable Turnover Ratio: Numerator= Total Sales
Denominator= Average Trade Receivables
- vi. Trade Payable Turnover Ratio: Numerator= Total Purchases
Denominator= Average Trade Payables
- vii. Net Capital Turnover Ratio: Numerator= Revenue from operations
Denominator= Working Capital (i.e. Current Assets - Current
- viii. Net Profit ratio: Numerator= Net Profit after tax
Denominator= Revenue from operations
- ix. Return on Equity ratio: Numerator= Net Profit after tax
Denominator= Average Shareholder's Equity
- x. Return on Capital Employed: Numerator= Earning before interest and taxes
Denominator= Total Network+ Total Debt+ Total Deferred Tax



Note 27.4: Reasons for more than 25% increase/ (decrease) in above ratios

Particulars	% change from
Current Ratio	Not Significant
Debt-Equity Ratio	The change is on account of issue of equity share capital during the year by the Company
Debt Service Coverage ratio	The Change is on account of increase in Profits before Interest and depreciation of the Company due to increase in revenue.
Inventory Turnover ratio	Not Significant
Trade Receivable Turnover Ratio	Not Significant
Trade Payable Turnover Ratio	Not Significant
Net Capital Turnover Ratio	Not Significant
Net Profit ratio	The Change is on account of increase in Profits of the Company due to increase in revenue.
Return on Equity ratio	The Change is on account of increase in Profits during the year and issue of Equity Share Capital by the Company during the year
Return on Capital Employed	The Change is on account of increase in Profits before Interest and depreciation of the Company due to increase in revenue and issue of equity share capital by the Company.
Return on Investment	Not Applicable



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

28 Capital and Other Commitments	(Rs. in Lacs)	
	As at 31st March 2024	As at 31st March 2023
a) Capital Commitments		
Estimated amount of contracts remaining to be executed on capital account not provided for (Net of Advances)	16.79	3.58

29 Earning Per Share (EPS)	Rs. In Lacs	
	Year ended 31st March, 2024	Year ended 31st March, 2023
Particulars		
Net profit after Tax	1.20	(167.59)
Profit / (Loss) attributable to the Equity Shareholders	1.20	(167.59)
Basic / Weighted Average Number of Equity Shares Outstanding during the year	2,19,82,192	1,37,24,932
Earning Per Share (in Rupees)		
- Basic	0.01	(1.22)
- Diluted	0.01	(1.22)
Nominal value of Equity Shares	10.00	10.00

30 The Micro, Small and Medium Enterprises have been identified by the Company from the available information, which has been relied upon by the auditors. According to such identification, the disclosures as per Section 22 of "The Micro, Small and Medium Enterprise Development (MSMED) Act, 2006" are as follows:

Details of dues to Micro and Small Enterprises as per MSMED Act, 2006	Rs. In Lacs	Rs. In Lacs
	31st March, 2024	31st March, 2023
The principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year	-	-
- Principal Amount	241.02	-
- Interest thereon	8.65	-
The amount of interest paid by the buyer in terms of section 16 of the Micro Small and Medium Enterprise Development Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro Small and Medium Enterprise Development Act, 2006.	-	-
Amount of interest accrued and remaining unpaid	8.65	-
The amount of interest accrued and remaining unpaid at the end of the accounting year; and the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the Micro Small and Medium Enterprise Development Act, 2006.	-	-

31 Employee Benefits

Defined contribution plan

i) The company has recognized, in statement of Profit & Loss for year ended 31st March, 2024 an amount of Rs. 38.92 Lacs (Previous year Rs. 26.72 Lacs) under defined contribution plans.

Expense under defined contribution plans include:	Year ended	Year ended
	31st March, 2024	31st March, 2023
a) Employer's contribution to provident fund	31.70	24.66
b) Employer's contribution to Employee State Insurance Corporation	2.47	1.91
c) Employer's contribution to Labour Welfare Fund	0.18	0.15
d) Employer's Contribution to National Pension Scheme	4.57	-
	38.92	26.72

The expense is disclosed in the line item - contribution to provident fund and other funds in Note 21



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

Defined benefit plan

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of the service gets a gratuity on retirement / termination at 15 days salary (last drawn salary) for each completed year of service. The Company has also provided for long-term compensated absences.

i)

	Gratuity (unfunded)		Leaves (unfunded)	
	31st March, 2024	31st March, 2023	31st March, 2024	31st March, 2023
(i) Reconciliation of opening and closing balances of obligations:				
a) Obligation at the beginning	3.69	1.75	16.75	7.74
b) Current Service Cost	2.95	2.07	12.80	12.15
c) Interest Cost	0.28	0.13	1.24	0.66
d) Past Service Cost	-	-	-	-
e) Actuarial (Gain) / Loss	0.38	(0.26)	(2.61)	(0.45)
f) Benefits paid	(0.27)	-	(5.68)	(3.35)
g) Obligation at the period end	7.03	3.69	22.50	16.75
(ii) Change in Plan Assets (Reconciliation of opening and closing balances):				
a) Fair Value of Plan Assets at beginning	-	-	-	-
b) Prior Period Adjustment	-	-	-	-
c) Expected return on Plan Asset	-	-	-	-
d) Contributions	-	-	-	-
e) Benefits paid	-	-	-	-
f) Actuarial Gain / (Loss) on Plan Assets	-	-	-	-
g) Fair Value of Plan Assets at period end	-	-	-	-
(iii) Reconciliation of fair value of assets and obligations:				
a) Present value of obligation at period end	7.03	3.69	22.50	16.75
b) Fair Value of Plan Assets at period end	-	-	-	-
c) Asset / Liability recognized in the Balance Sheet	7.03	3.69	22.50	16.75
(iv) Amount recognized in the income statement				
a) Current Service Cost	2.95	2.07	12.15	12.15
b) Past Service Cost	-	-	-	-
c) Interest Cost	0.28	0.13	0.57	0.57
d) Curtailment Cost (Credit)	-	-	-	-
e) Expected return on Plan Assets	-	-	-	-
f) Actuarial (Gain) / Loss	(0.38)	(0.26)	(0.45)	(0.45)
g) Expenses recognized during the period	2.85	1.94	12.27	12.27
(v) Other Comprehensive Income (OCI)				
a) Unrealised actuarial Gain / (Loss)	(0.38)	0.26	2.61	0.45



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

	As at 31st March, 2024	As at 31st March, 2023
(vi) Assumptions:		
a) Discounting Rate (per annum)	7.25%	7.39%
b) Future Salary Increase	5.00%	5.00%
Withdrawal / Employee Turnover Rate		
c) Age upto 30 years	36.00%	36.00%
d) Age from 31 to 44 years	32.00%	32.00%
e) Age above 44 years	15.00%	15.00%
Mortality table used	Indian Assured Lives Mortality (2012-14)	Indian Assured Lives Mortality (2012-14)

Maturity Profile of Defined Benefit Obligation

Year	Amount
0 to 1 Year	0.19
1 to 2 Year	0.91
2 to 3 Year	1.13
3 to 4 Year	0.90
4 to 5 Year	0.65
5 to 6 Year	0.41
6 Year onwards	2.83

The estimates of future salary increases, considered in actuarial valuation, take into account inflation, seniority, promotion and other relevant factors including supply and demand in the employment market.

Significant actuarial assumption for the determination of the defined obligation are discounted rate, expected salary escalation rate and withdrawal rate. The sensitivity analyses below have been determined based on reasonably possible changes of the respective assumption occurring at the end of the reporting period, while holding all other assumptions constant.

The above information is certified by the actuarial valuer.

Enterprise best estimate of contribution during next year is Rs. 4.36 Lacs for Gratuity & Rs. 10.94 Lacs for Leave Encashment.

The discount rate is based on prevailing market yield of Govt. Bonds as at the date of valuation.

Particulars	Year ended 31st March, 2024		Year ended 31st March, 2023	
	Increase	Decrease	Increase	Decrease
Change in discount rate by 0.50%	(0.16)	0.17	(0.09)	0.10
Change in Salary escalation rate by 0.50%	0.17	(0.16)	0.10	(0.10)

Sensitivity due to mortality and withdrawals are not material & hence impact of change not calculated.

Sensitivity as to rate of inflation, rate of increase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a lump sum benefit on retirement.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.
32 Financial Instruments

i) **Capital Management**

The Company manages its capital to ensure that the Company will be able to continue as going concern while maximising the return to stakeholders through the optimisation of the debt and equity balance.

The capital structure of the Company consists of net debt (borrowings as Detailed in Notes 13 offset by cash and bank balances) and total equity of the company.

The Company is not subject to any externally imposed capital requirements other than for covenants under various loan arrangements of the Company.

The Company's Board reviews the capital structure of the Company on need basis. As part of this review, the Board considers the cost of capital and the risks associated with each class of capital. The gearing ratio as at 31st March 2024 78% (127%, 31st March 2023)

Gearing Ratio :

The gearing ratio at end of the reporting period was as follows :

Particulars	(Rs. In Lacs)	
	As at March 31,2024	As at March 31,2023
Debt *	1,541.40	1,772.24
Less : Cash and Bank Balances (Refer Note 8)	135.30	120.26
Net Debt	1,406.10	1,651.98
Total Equity	1,808.70	1,297.79
Net Debt to Equity Ratio	78%	127%

* Debt is defined as long-term and short-term borrowings.

ii) **Categories of Financial Instruments**

Financial Assets	(Rs. In Lacs)	
	As at 31st March 2024	As at 31st March 2023
Measured at amortised cost	1,132.38	846.80
Trade receivables - Current	135.30	120.26
Cash and cash equivalents - Current	205.00	141.00
Other Bank balances - Current	1.66	1.49
Loans	23.91	8.40
Other Financial Assets		
Total	1,498.25	1,117.95

At the end of the reporting period, there are no significant concentrations of financial assets designated at FVTPL. The carrying amount reflected above represents the Company's maximum exposure to credit risk for such financial assets.

Financial Liabilities	(Rs. In Lacs)	
	As at 31st March 2024	As at 31st March 2023
Measured at amortised cost	1,123.00	1,533.14
Borrowings - Non Current	412.49	252.40
Borrowings - Current	558.74	503.80
Trade payables - Current	46.53	78.59
Other financial liabilities - Current		
Total	2,140.76	2,367.93



Note
No.

ii) **Financial Risk Management Objectives**

The Company's Corporate Treasury function provides services to the business, co-ordinates access to domestic and international financial markets, monitors and manages the financial risks including market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The Board of Directors manages the financial risk of the Company through internal risk reports which analyse exposure by magnitude of risk. The Company has no exposure from the international market as the Company's operations are in India. The Company has no exposure towards foreign currency risk as it earns no revenue in foreign currency.

Market Risk

The Company's activities expose it primarily to the financial risks of changes in interest rates.

a) **Interest Rate risk management**

The Company is exposed to interest rate risk because Company borrow funds at both fixed and floating interest rates. The risk is managed by the Company by maintaining an appropriate mix between fixed and floating rate borrowings.

The Company's exposures to interest rates on financial assets and financial liabilities are detailed in the liquidity risk management section of this note.

Interest Rate sensitivity analysis

The sensitivity analyses below have been determined based on the exposure to interest rates at the end of the reporting period. For floating rate liabilities, the analysis is prepared assuming the amount of the liability outstanding at the end of the reporting period was outstanding for the whole year. A 100 basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

	(Rs. In Lacs)	(Rs. In Lacs)
	Interest Impact	Interest Impact
	As at 31st March 2024	As at 31st March 2023
If increase by 1% in interest rates		
Particulars		
Increase / (decrease) in profit or loss for the year	(15.35)	(17.66)
Increase / (decrease) in total equity as at the end of the reporting period	(15.35)	(17.66)
If decrease by 1% in interest rates		
Particulars	Interest Impact	Interest Impact
	As at 31st March 2024	As at 31st March 2023
Increase / (decrease) in profit or loss for the year	15.35	17.66
Increase / (decrease) in total equity as at the end of the reporting period	15.35	17.66

b) **Credit Risk Management**

Credit risk refers to the risk that a counter party will default on its contractual obligations resulting in financial loss to the Company. The Company takes due care while extending any credit as per the approval matrix approved by Board of Directors.

c) **Liquidity risk management**

Ultimate responsibility for liquidity risk management rests with the board of directors, which has established an appropriate liquidity risk management framework for the management of the company's short-term, medium-term and long-term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. Note given below sets out details of additional undrawn facilities that the Company has at its disposal to further reduce liquidity risk.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities

Particulars	Within 1 year	1 - 2 years	More than 2 years	Total	Rs. In Lacs
					Carrying Amount (net of transaction cost)
As at 31st March 2024					
Borrowings	412.49	536.33	589.04	1,537.86	1,535.49
Trade Payables	558.74	-	-	558.74	558.74
Interest accrued but not due on borrowings	5.91	-	-	5.91	5.91
Other Financial Liabilities	40.62	-	-	40.62	40.62
Total	1,017.76	536.33	589.04	2,143.13	2,140.76
As at 31st March 2023					
Borrowings	252.40	412.49	1,125.36	1,790.25	1,785.54
Trade Payables	503.80	-	-	503.80	503.80
Interest accrued but not due on borrowings	6.70	-	-	6.70	6.70
Other Financial Liabilities	71.89	-	-	71.89	71.89
Total	834.79	412.49	1,125.36	2,372.64	2,367.93



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

33 Related party disclosure

a) Name of related parties

Parties where control exists irrespective of whether transactions have occurred or not	Constructive Finance Private Limited
Ultimate Parent Company	
Holding Company	Artemis Medicare Services Limited
Names of other related parties with whom transactions have taken place during the year	
Key Management Personnel	Dr. Kapil Mohan (CEO) Mr. Joginder Singh (CFO)
Enterprises having significant influence	Philips Medical Systems Nederland BV Apollo Tyres Centre of Excellence Ltd. Apollo Supply Chain Pvt. Ltd

b) Transactions during the year

(Rs. In Lacs)

Particulars	Holding Company		Key Management Personnel & their relatives		Enterprises having significant influence	
	For the year ended		For the year ended		For the year ended	
	31st March, 2024	31st March, 2023	31st March, 2024	31st March, 2023	31st March, 2024	31st March, 2023
Purchase of Property, Plant & Equipment	-	16.21			-	-
Reimbursement of Expenses incurred on behalf of the Company	14.00	33.28			-	-
Corporate Guarantee Fee	3.08	1.13				
Purchase of medical consumables	-	14.07				
Interest on Inter Corporate Loan	0.43	2.52			178.50	329.00
Issue of Share Capital	331.50	611.00			2.53	1.42
Rent paid		-				
Loan received		155.00				
Loan repaid	20.00	135.00				
Corporate Guarantee Taken		1,000.00				
KMP-Compensation						
Dr. Kapil Mohan			52.57	16.60		
Mr. Joginder Singh			31.36	11.12		
Defined Benefit Obligation (DBO)						
Dr. Kapil Mohan			1.29	0.52		
Post-Employment Benefits			4.54	3.31		
Short-term benefits						
Total- DBO			5.83	3.83		
Mr. Joginder Singh			0.51	0.15		
Post-Employment Benefits			2.30	1.12		
Short-term benefits						
Total- DBO			2.81	1.27		

* Transactions are reported including taxes.

(Rs. In Lacs)

Balances as at the end of the year

Relation	Name of Related Party	31st March, 2024	31st March, 2023
Key Management Personnel & their relatives	Dr. Kapil Mohan	3.01	2.92
	Mr. Joginder Singh	1.82	1.33
Holding Company	Artemis Medicare Services Limited	-	39.05
Holding Company	Artemis Medicare Services Limited-Corporate Guarantee	2,500.00	2500.00
Enterprises having significant influence	Apollo Tyres Centre of Excellence Ltd.	-	-

34 Disclosure under Ind AS - 115 (Revenue from contracts with customers)

31st March
2024 31st March 2023
(Rs. In Lacs) (Rs. In Lacs)

a. Disaggregated revenue information

Type of Services or goods	3,270.39	2,142.46
Revenue from Healthcare Services	64.19	178.95
Revenue from Sales of Drugs and Consumables	3,334.58	2,321.41
Total		
Revenue from Contracts with Customers	3,334.58	2,321.41
Revenue from Customers based in India	3,334.58	2,321.41
Total		
Timing of Revenue Recognition	3,270.39	2,142.46
Services transferred over time (Healthcare Services)	64.19	178.95
Goods (Pharmacy and consumable) transferred at a point of time	3,334.58	2,321.41
Total		



Note
No.

b. Trade receivables and Contract Customers

Trade Receivables (includes GST)	1,132.38	846.80
Unbilled revenue	12.55	6.38
Total	1,144.93	853.18

Trade receivables are non-interest bearing and are generally on terms of 0- 90 days. Rs. 38.59 Lakhs(Previous Year Rs. 31.65) was recognised as provision for expected credit losses on trade receivables.

Trade receivables are presented net of impairment in the Balance sheet.

The three largest customer have total share in revenue for the period ended March 31,2024 : 50% (March 31,2023: 56%) and in receivables as at March 31,2024 68% (March 31,2023 68%)

c. Performance obligation and remaining performance obligation

The remaining performance obligation disclosure provides the aggregate amount of the transaction price yet to be recognized as at the end of the reporting period and an explanation as to when the Company expects to recognize these amounts in revenue. There were no remaining performance obligation as the same is satisfied upon delivery of goods/services

35 Lease

The company incurred Rs. 7.82 lacs for the year ended March 31,2024 (Previous year Rs 1.83 Lacs) towards expenses relating to short term leases and leases of low value assets.

36

The Parliament of India has approved the Code on Social Security, 2020(the Code) which may impact the contribution by the Company towards provident fund, gratuity and ESI. The Code have been published in Gazette of India however, the effective date has not yet been notified. The Company will assess the impact of the code when it comes into effect and will record any related impact in the period the Code becomes effective,if any.

37

Other Disclosures as required under Schedule III of the Companies Act, 2013

i Details of Benami Property held

No proceedings have been initiated on or are pending against the company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

ii Wilful Defaulter

The company has not been declared Wilful defaulter by any bank or financial institution or government or any government authority.

iii Compliance with number of layers of companies

The company does not have any subsidiary accordingly this clause is not applicable .

iv Compliance with approved scheme(s) of arrangements

The company has not entered into any scheme of arrangement which has an accounting impact on current year

v Loans to promoters, directors, KMPs and other related parties

During the year, the Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties (as defined under the Companies Act, 2013), either severally or jointly with any other person that are either:

(a) repayable on demand or

(b) without specifying any terms or period of repayment.



Artemis Cardiac Care Private Limited
Notes to Financial Statements for the Year ended 31st March, 2024

Note
No.

- vi **Loans and Advances**
A. The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
b. provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries
B. The company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall:
a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
b. provide any guarantee, security or the like on behalf of the ultimate beneficiaries
- vii **Undisclosed income**
There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.
- viii **Details of Crypto currency or Virtual currency**
The company has not traded or invested in crypto currency or virtual currency during the current or previous year.
- ix **Valuation of Property, Plant and Equipment and intangible asset and investment property**
The company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous year.
- x **Registration of charges or satisfaction with Registrar of Companies**
The Company has complied with registration of charge for loan taken during the year
- xi **Utilization of borrowings availed from banks and financial institutions**
The company has availed loans from Bank during the year ended 31st March 2024 and has utilised the same for the purpose it was taken for .
- xii The Company has not declared or paid dividend during the year ended 31st March 2024.
- xiii **Title deeds**
The Company does not own any freehold land and hence the disclosure on title deeds of the freehold land is held in the name of the Company is not applicable.
- xiv **Fair Valuation of Investment Properties**
The Company does not hold any investment property and hence the disclosure on fair valuation of investment property is not applicable to the Company.
- xv **Returns to Banks**
The Company is not required to file quarterly returns to the banks as per terms of the sanction letter.
- xvi **Transaction with Companies Struck of under section 248 of the Companies Act, 2013**
The Company has no Transaction with companies struck of under section 248 of the Companies Act, 2013
- 38 The accounting software used for maintaining its books of account, has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensured that the audit trail has not been disabled. Further, there were no instance of audit trail feature being tampered with
- 38 On 20th September 2019, the Government of India vide the Taxation Laws (Amendment) Ordinance 2019, inserted Section 115BAA in the Income Tax Act, 1961, which provides domestic companies an option to pay income tax at reduced rate effective 1st April 2019, subject to certain conditions. The Company has opted for lower rate of taxation during financial year 2023-24 and accordingly tax expenses for the year ended 31st March 2024 have been provided for at reduced tax rate.

As per our report of even date attached
For SCV & Co. LLP
Chartered Accountants
Firm Registration Number 000235N / N500089

(Sunny Singh)
Partner
Membership No. 516834

Place : Noida
Dated: 8th May 2024



For and on behalf of the Board of Directors
of Artemis Cardiac Care Private Limited

Dr. Devlina Chakravarty
[Director]
[DIN : 07107875]

Dr. Kapil Mohan
[Chief Executive Officer]

Place : Gurugram
Dated: 8th May 2024

Dr. (Brig.) Anil Khejarpa
[Director]
[DIN : 09784377]

Joginder Singh
[Chief Financial Officer]



Poonam Makkar
[Company Secretary]